Bio

Bio


I grew up hiking in the Wasatch Mountains and, after completing college in Utah, I moved to Philadelphia to attend medical school at the University of Pennsylvania in 2005. After graduating in 2009, I came to Stanford for my general internal medicine internship and residency, was invited to stay as a chief resident in 2012, and then stayed again for oncology/hematology fellowship in 2013 before joining the faculty of the division of oncology in 2016. Here at Stanford I pursue my twin passions of providing excellent clinical care and mentoring the next generation of physicians.

I specialize in the care of patients who have gastrointestinal tumors, including tumors of the pancreas, large and small bowel, liver, and biliary tree. I have experience with rare GI tumors--including both intra and extra hepatic cholangiocarcinoma--and trained under Dr. Pamela Kunz, one of the country's leading experts in the care of patients with neuroendocrine tumors and have thus seen a large number of these patients, as well.

I am lucky to have a first rate medical team by my side consisting of a nurse coordinator, a nurse practitioner, and a physician assistant. We strive together to provide capable, compassionate, responsive care and make the care of our patients our highest priority.

In addition to patient care, I am a devoted medical teacher and have worked over the past five years to elevate the teaching of medicine at Stanford University, where I have taught medical students, residents, and fellows, including conducting a randomized, controlled trial hoping to optimize the way we teach communication skills to nascent physicians.

Fluent in Spanish, I have lived in both Mexico and Argentina and am comfortable in virtually all medical situations conversing fluently in Spanish without an interpreter. I especially enjoy providing care to patients who speak Spanish as a first language.

Clinical Focus


  • Oncology, specializing in the care of tumors of the gastrointestinal tract
  • Oncology

Academic Appointments


Administrative Appointments


  • Assistant Director of Inpatient Oncology Service, Stanford University Hospital (2016 - Present)

Honors & Awards


  • Stanford Internal Medicine Residency Chief REsident, Stanford Internal Medicine Residency Program (2012-2013)
  • Heritage Scholar (4 year full tuition scholarship), Brigham Young University (1999-2005)
  • National Merit Scholar, National Merit Scholarship Corporation (1999)

Professional Education


  • Fellowship: Stanford University Hematology and Oncology Fellowship (2016) CA
  • Residency: Stanford University Internal Medicine Residency (2013) CA
  • Board Certification: American Board of Internal Medicine, Oncology (2016)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2012)
  • Medical Education: University of Pennsylvania Registrar's Office (2009) PA

Community and International Work


  • HIV/TB care in South Africa

    Topic

    Serving patients with HIV and TB in South Africa

    Populations Served

    Indigent patients

    Location

    International

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

  • Healthcare in Argentina, Buenos Aires, Argentina

    Topic

    Providing Healthcare

    Populations Served

    BMT patients

    Location

    International

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

Teaching

Stanford Advisees


Publications

All Publications


  • In Support of a Complex IDEA-A New Meta-analysis Supporting the Findings of the International Duration Evaluation of Adjuvant Therapy Collaboration. JAMA network open Johnson, T. 2019; 2 (5): e194161

    View details for DOI 10.1001/jamanetworkopen.2019.4161

    View details for PubMedID 31099858

  • Thrombophilia testing in the inpatient setting: impact of an educational intervention. BMC medical informatics and decision making Kwang, H. n., Mou, E. n., Richman, I. n., Kumar, A. n., Berube, C. n., Kaimal, R. n., Ahuja, N. n., Harman, S. n., Johnson, T. n., Shah, N. n., Witteles, R. n., Harrington, R. n., Shieh, L. n., Hom, J. n. 2019; 19 (1): 167

    Abstract

    Thrombophilia testing is frequently ordered in the inpatient setting despite its limited impact on clinical decision-making and unreliable results in the setting of acute thrombosis or ongoing anticoagulation. We sought to determine the effect of an educational intervention in reducing inappropriate thrombophilia testing for hospitalized patients.During the 2014 academic year, we implemented an educational intervention with a phase implementation design for Internal Medicine interns at Stanford University Hospital. The educational session covering epidemiology, appropriate thrombophilia evaluation and clinical rationale behind these recommendations. Their ordering behavior was compared with a contemporaneous control (non-medicine and private services) and a historical control (interns from prior academic year). From the analyzed data, we determined the proportion of inappropriate thrombophilia testing of each group. Logistic generalized estimating equations were used to estimate odds ratios for inappropriate thrombophilia testing associated with the intervention.Of 2151 orders included, 934 were deemed inappropriate (43.4%). The two intervention groups placed 147 orders. A pooled analysis of ordering practices by intervention groups revealed a trend toward reduction of inappropriate ordering (p = 0.053). By the end of the study, the intervention groups had significantly lower rates of inappropriate testing compared to historical or contemporaneous controls.A brief educational intervention was associated with a trend toward reduction in inappropriate thrombophilia testing. These findings suggest that focused education on thrombophilia testing can positively impact inpatient ordering practices.

    View details for DOI 10.1186/s12911-019-0889-6

    View details for PubMedID 31429747

  • Reclaiming Reality Doctoring and Discipleship in a Hyperconnected Age BYU STUDIES QUARTERLY Johnson, T. 2018; 57 (3): 7–38
  • A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback. Postgraduate medical journal Hom, J. n., Kumar, A. n., Evans, K. H., Svec, D. n., Richman, I. n., Fang, D. n., Smeraglio, A. n., Holubar, M. n., Johnson, T. n., Shah, N. n., Renault, C. n., Ahuja, N. n., Witteles, R. n., Harman, S. n., Shieh, L. n. 2017

    Abstract

    Most residency programmes do not have a formal high value care curriculum. Our goal was to design and implement a multidisciplinary high value care curriculum specifically targeted at interns.Our curriculum was designed with multidisciplinary input from attendings, fellows and residents at Stanford. Curricular topics were inspired by the American Board of Internal Medicine's Choosing Wisely campaign, Alliance for Academic Internal Medicine, American College of Physicians and Society of Hospital Medicine. Our topics were as follows: introduction to value-based care; telemetry utilisation; lab ordering; optimal approach to thrombophilia work-ups and fresh frozen plasma use; optimal approach to palliative care referrals; antibiotic stewardship; and optimal approach to imaging for low back pain. Our curriculum was implemented at the Stanford Internal Medicine residency programme over the course of two academic years (2014 and 2015), during which 100 interns participated in our high value care curriculum. After each high value care session, interns were offered the opportunity to complete surveys regarding feedback on the curriculum, self-reported improvements in knowledge, skills and attitudinal module objectives, and quiz-based knowledge assessments.The overall survey response rate was 67.1%. Overall, the material was rated as highly useful on a 5-point Likert scale (mean 4.4, SD 0.6). On average, interns reported a significant improvement in their self-rated knowledge, skills and attitudes after the six seminars (mean improvement 1.6 points, SD 0.4 (95% CI 1.5 to 1.7), p<0.001).We successfully implemented a novel high value care curriculum that specifically targets intern physicians.

    View details for PubMedID 28663352

  • Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis Mou, E., Kwang, H., Hom, J., Shieh, L., Ahuja, N., Harman, S., Johnson, T., Kumar, A., Shah, N., Witteles, R., Berube, C. AMER SOC HEMATOLOGY. 2016
  • Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Clinical advances in hematology & oncology : H&O Varma, G., Johnson, T. P., Advani, R. H. 2016; 14 (7): 543-554

    Abstract

    The development of Bruton's tyrosine kinase (BTK) inhibitors and their introduction into clinical practice represent a major advance in the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. Although ibrutinib is the only BTK inhibitor that has been approved by the US Food and Drug Administration, several others are under investigation. Ibrutinib is currently approved for use in relapsed/refractory CLL, CLL with 17p deletion (del[17p]), relapsed or refractory mantle cell lymphoma, and Waldenström macroglobulinemia. Although it is clear that ibrutinib has altered treatment paradigms and outcomes in these diseases, several questions remain regarding (1) its role in frontline vs salvage therapy; (2) its use as a single agent vs in combination with biologic agents, other small molecules, or traditional chemoimmunotherapy; (3) the optimal duration of treatment; and (4) the treatment of patients who cannot tolerate or have disease resistant to ibrutinib. Because sparse clinical data are available on other BTK inhibitors, it is unclear at present whether their clinical efficacy and toxicity will differ from those of ibrutinib.

    View details for PubMedID 27379948

  • Empathy and the Atonement BYU STUDIES QUARTERLY Johnson, T. 2016; 55 (4): 105-122
  • Throughput. Annals of internal medicine Johnson, T. 2011; 155 (2): 133-?

Latest information on COVID-19